To the Editor:
Zhang et al.
1
recently reported that among 70 patients with NSCLC who carried CHEK2 pathogenic germline variants (PGVs), 29 (41.4%) had tumor “potentially actionable driver alterations,” and that KRAS mutations constituted 51.7% of those identified driver alterations. Their report raises several key questions, including universal germline testing of patients with NSCLC, the implications of identifying CHEK2 PGV carriers, and the potential clinical significance of the dual biomarker, somatic KRAS/CHEK2 PGV.1
As the authors noted, CHEK2 PGVs in patients with NSCLC are rare (<1%), and, therefore, universal germline testing of patients with NSCLC to identify CHEK2 PGV carriers is problematic.
1
However, germline testing is recommended for all patients with tumors exhibiting probable incidental CHEK2 PGVs; the current routine next-generation sequencing of NSCLCs will—when CHEK2 is interrogated—identify probable incidental CHEK2 PGVs, and, therefore, a group that particularly should consider undergoing germline testing.2
- Daly M.B.
- Pal T.
- AlHilli Z.
- et al.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Genetic/familial high-risk assessment: breast, ovarian, and pancreatic.
https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503
Date accessed: November 15, 2022
The authors propose further studies to determine whether CHEK2 PGVs are NSCLC-predisposing.
1
In the meantime, it is important to recognize that CHEK2 PGVs are considered “actionable,” regardless of whether these PGVs are eventually proven to be NSCLC-predisposing. For example, the National Comprehensive Cancer Network recommends that patients identified with CHEK2 PGVs consider annual breast magnetic resonance imaging (because of their 20%–40% lifetime risk of breast cancer) and more aggressive screening for colorectal cancer, particularly when there is a family history of colorectal cancer.2
,- Daly M.B.
- Pal T.
- AlHilli Z.
- et al.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Genetic/familial high-risk assessment: breast, ovarian, and pancreatic.
https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503
Date accessed: November 15, 2022
3
In addition, there are therapeutic clinical trials for patients diagnosed with a variety of cancer types for patients with CHEK2 PGVs, and cascade germline testing is recommended for family members of patients carrying CHEK2 PGVs.- Gupta S.
- Weiss J.M.
- Axell L.
- et al.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Colorectal.
https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1436
Date accessed: November 15, 2022
2
,- Daly M.B.
- Pal T.
- AlHilli Z.
- et al.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Genetic/familial high-risk assessment: breast, ovarian, and pancreatic.
https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503
Date accessed: November 15, 2022
4
US National Library of Medicine
ClinicalTrials.gov.
ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/results?cond=&term=CHEK2+germline&cntry=&state=&city=&dist=
Date accessed: November 15, 2022
Zhang et al.
1
also reported that NSCLCs of patients carrying CHEK2 PGVs frequently had actionable RAS mutations. Studies are also needed to determine whether the response rate and other clinical benefits of KRAS inhibitors are different in patients who carry CHEK2 PGVs compared with those patients who do not carry CHEK2 PGVs. As a related example, Jung et al.5
recently found that dual TP53/EGFR tumor mutations predicted a poorer recurrence-free survival with treatment compared with that of patients with EGFR-mutated NSCLCs whose tumors have no TP53 mutation.It is hoped that the report by Zhang et al.
1
will prompt future studies to establish with more certainty whether CHEK2 PGVs are NSCLC-predisposing, which patients with NSCLC should undergo germline testing for CHEK2 PGVs and studies aimed to assess the clinical significance and therapeutic implications of dual somatic KRAS/CHEK2 PGVs in patients with NSCLC.CRediT Authorship Contribution Statement
Steven Sorscher: Conceptualization, Methodology, Investigation, Writing-original draft, Writing-review & editing, Supervision, Funding acquisition.
Data Availability
All data/statements in this perspective is either referenced in the text or the opinion of the author (Dr. Sorscher). The data that supports the findings/statements in this perspective is openly available in the references provided.
References
- A high percentage of NSCLC with germline CHEK2 mutation harbors actionable driver alterations: survey of cancer genomic database and review of the literature.JTO Clin Res Rep. 2022; 3: 100387
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Genetic/familial high-risk assessment: breast, ovarian, and pancreatic.(Version 1.2023)https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503Date accessed: November 15, 2022
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Colorectal.(Version 1.2022)https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1436Date accessed: November 15, 2022
- ClinicalTrials.gov.https://clinicaltrials.gov/ct2/results?cond=&term=CHEK2+germline&cntry=&state=&city=&dist=Date accessed: November 15, 2022
- Clinical, pathologic, and molecular prognostic factors in patients with early-stage EGFR-mutant NSCLC.Clin Cancer Res. 2022; 28: 4312-4321
Article info
Publication history
Published online: November 18, 2022
Footnotes
Cite this article as: Sorscher S. CHEK2 pathogenic germline variants in patients with NSCLC. JTO Clin Res Rep. 2022;3:100439.
Identification
Copyright
© 2022 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- In Response to Dr. Steven SorscherJTO Clinical and Research ReportsVol. 4Issue 1
- PreviewWe thank Dr. Sorscher for his interest and compliments on our report on germline CHEK2 mutation (gCHEK2m).1 First, we agree that routine germline testing of patients with NSCLC is neither practical nor recommended as most patients with NSCLC have a smoking history. Even among never-smokers with NSCLC, gCHEK2m is extremely rare. Nevertheless, the routine use of plasma genotyping in assessing resistance to targeted therapies, to perform initial genomic profiling to identify actionable alterations, or to monitor response to treatment is in fact in the majority of the cases performing de facto germline testing because (at least a subset of, but not all) most plasma genotyping assays sequence most of the common hereditary genetic mutations (APC, ATM, BRCA1, BRCA2, CHECK2, etc.) even if they are not purposed for germline testing.
- Full-Text
- Preview
